Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongkai Ji

Showing results (151-160 of 170) with videos related to

Pageof 17
Sort By:
Science (New York, N.Y.)|January 17, 2025
Distinct myeloid-derived suppressor cell populations in human glioblastomaChristina Jackson, Christopher Cherry, Sadhana Bom, et al.
Nature Methods|February 8, 2022
NTR 2.0: a rationally engineered prodrug-converting enzyme with substantially enhanced efficacy for targeted cell ablationAbigail V Sharrock, Timothy S Mulligan, Kelsi R Hall, et al.
Cell Reports|May 3, 2024
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancerRyan Blawski, Bujamin H Vokshi, Xinyu Guo, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
Immune checkpoint inhibitors amplify type 2 immune mediated repair by pro-regenerative scaffoldsJordan Garcia, Anna Ruta, Frank Haoning Yu, et al.
Iscience|February 18, 2026
Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatmentVito W Rebecca, Min Xiao, Andrew Kossenkov, et al.
Cell|September 7, 2024
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapyYash Chhabra, Mitchell E Fane, Sneha Pramod, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2020
Metabolic programs define dysfunctional immune responses in severe COVID-19 patientsElizabeth A Thompson, Katherine Cascino, Alvaro A Ordonez, et al.
Cell Reports|March 10, 2021
Metabolic programs define dysfunctional immune responses in severe COVID-19 patientsElizabeth A Thompson, Katherine Cascino, Alvaro A Ordonez, et al.
Immunity|October 14, 2019
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate DecisionZeyu Chen, Zhicheng Ji, Shin Foong Ngiow, et al.
Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.
Pageof 17

Showing results (151-160 of 170) with videos related to

Sort By:
Pageof 17
Science (New York, N.Y.)|January 17, 2025
Distinct myeloid-derived suppressor cell populations in human glioblastomaChristina Jackson, Christopher Cherry, Sadhana Bom, et al.
Nature Methods|February 8, 2022
NTR 2.0: a rationally engineered prodrug-converting enzyme with substantially enhanced efficacy for targeted cell ablationAbigail V Sharrock, Timothy S Mulligan, Kelsi R Hall, et al.
Cell Reports|May 3, 2024
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancerRyan Blawski, Bujamin H Vokshi, Xinyu Guo, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
Immune checkpoint inhibitors amplify type 2 immune mediated repair by pro-regenerative scaffoldsJordan Garcia, Anna Ruta, Frank Haoning Yu, et al.
Iscience|February 18, 2026
Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatmentVito W Rebecca, Min Xiao, Andrew Kossenkov, et al.
Cell|September 7, 2024
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapyYash Chhabra, Mitchell E Fane, Sneha Pramod, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2020
Metabolic programs define dysfunctional immune responses in severe COVID-19 patientsElizabeth A Thompson, Katherine Cascino, Alvaro A Ordonez, et al.
Cell Reports|March 10, 2021
Metabolic programs define dysfunctional immune responses in severe COVID-19 patientsElizabeth A Thompson, Katherine Cascino, Alvaro A Ordonez, et al.
Immunity|October 14, 2019
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate DecisionZeyu Chen, Zhicheng Ji, Shin Foong Ngiow, et al.
Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.
Pageof 17